a110

A110 is a potent and selective IMPDHs inhibitor. It binds to the NAD(+) cofactor site and forms a ternary complex with IMP.

(S)-Phe-A110/B319 is a selective binder with a 20-fold higher affinity for the H1047R mutant of the p110α subunit within the p110α/p85α PI3K complex.

(R)-Phe-A110/B319 is a hapten and a selective binder for tumor-associated antigens. It exhibits a 20-fold higher affinity for the H1047R mutant of p110α within the p110α/p85α PI3K complex. This compound is applicable in studies on the activation of conditional chimeric antigen receptor T (CAR-T) cells and tumor targeting.

Pagibaximab is a human chimeric monoclonal antibody targeting lipoteichoic acid, a surface fatty acid of Staphylococcus, for preventing Staphylococcus infections.

Taltobulin trifluoroacetate is a synthetic analogue of the tripeptide hemiasterlin, is a potent agent of antimicrotubule that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

ICA 110381 is a KCNQ2/Q3 potassium channel opener for the treatment of epilepsy

PBA-1105 TFA is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. This compound selectively binds to the exposed hydrophobic regions of misfolded proteins, promoting their degradation through the autophagy (autophagy) pathway. Additionally, PBA-1105 TFA enhances the autophagic flux of Ub-bound aggregates.

DA-11004 is a potent NADP-dependent isocitrate dehydrogenase inhibitor (IC50: 1.49 μM for IDPc). DA-11004 inhibited fatty acid synthesis in adipose tissues via IDPc inhibition. It also decreased the plasma glucose levels and FFA in HF diet-induced obesity

RG-102240 is a ligand for the insect ecdysone receptor (EcR). Its IC50 values against wild-type G:CfE (DEF) and A110P mutant are 85 nM and 13 nM, respectively. It activates reporter gene expression of both wild-type CfEcR and the A110P mutant.

DAA-1106 is a potent and selective ligand for peripheral benzodiazepine receptor (PBR), acting as a potent and selective agonist at the peripheral benzodiazepine receptor.

Hydroxyfasudil Hydrochloride (HA 1100 hydrochloride) is a ROCK1/2 inhibitor (IC50s: 0.73/0.72 μM).

Hydroxyfasudil (Hydroxy-Fasudil) is a ROCK inhibitor(IC50s of 0.73 and 0.72 μM for ROCK1 and ROCK2, respectively).

PBA-1105, an autophagy-targeting chimeric molecule (AUTOTAC), facilitates the self-oligomerization of p62. Additionally, PBA-1105 enhances the autophagic flux of Ub-conjugated aggregates.

PBA-1105b, a longer PEGylated derivative of PBA-1105, is an autophagy-targeting chimeric compound (AUTOTAC) that can induce self-oligomerization of p62. It enhances the autophagic flux of Ub-bound aggregates.

Anti-PD-L1/B7-H1 Antibody (29E.2A3) represents a chimeric antibody of mouse IgG2b, κ type, specifically targeting human PD-L1/B7-H1. The recommended isotype control for this antibody is Mouse IgG2b kappa, Isotype Control.

TBL-100 is a human monoclonal antibody (mAb) that targets Tau. It is applicable for research in Alzheimer's disease (AD) and progressive supranuclear palsy.

BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin 23 (IL-23). It reduces IL-23-induced STAT3 phosphorylation, inhibits Th17 cell differentiation, and suppresses the release of pro-inflammatory cytokines such as IL-17 and TNF-α. BMS-986010 shows promise in research on autoimmune diseases, including psoriasis and Crohn's disease.

XOMA 129 is a human monoclonal antibody that targets the insulin receptor (INSR). This compound acts as an antagonist to the insulin receptor (IR), effectively inhibiting the decrease of blood glucose levels. XOMA 129 is applicable in the research of hypoglycemia.

PAT-LM1 is a human monoclonal antibody that targets NRB54/NONO. It is applicable in the study of hematological malignancies.

GSK-315234 is a human IgG1 monoclonal antibody (mAb) that targets OSM. It is applicable for research in atherosclerosis. Recommended isotype control: Human IgG1 kappa, Isotype Control.

Anti-FcgR3a / CD16a (AFM13) is a tetravalent bispecific antibody targeting human CD30 and human low-affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulatory and antitumor activities. Molecular weight: 124.56 kD.

Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA is an antibody-drug conjugate (ADC) composed of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked with the MC-Vc-PAB-DMEA-PEG2 connector and the DNA alkylator Duocarmycin SA. This compound is utilized in cancer research.

MEDI-7352 is a human bispecific antibody targeting NGF/bNGF and TNF. It can be utilized in research focused on osteoarthritis (OA) pain.

Aflibercept is a fully humanized recombinant fusion protein that acts as a decoy VEGF receptor and a “trap,” exhibiting binding affinity for VEGF-A, VEGF-B, and PIGF (placental growth factor). By blocking the binding of these ligands to endogenous VEGF receptors, it inhibits pathological angiogenesis and is used in both ophthalmology and oncology.